You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Solna, Sweden-based company is currently expanding from offering in situ sequencing services to selling kits.
Single Technologies is working on a new sequencing platform with faster imaging and smaller flow cells that will harness existing chemistries.
CUTseq uses enzyme-based fragmentation and in vitro transcription to barcode DNA, saving money when preparing 1,000 samples or more.
A study published this week describing the new approach shows higher resolution than an earlier method that 10x Genomics is commercializing.
A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.
Sweden's Science for Life Laboratory, SciLifeLab, will offer subsidized whole-genome sequencing to scientists through two national research programs that it plans to fund with a total of about $3 million over the coming year.
Roche still plans to make its high-density peptide microarrays available to customers in the future.
Name: Ulf Landegren
This is part one of a two-part interview. Part two is available here.
Name: Peter Nilsson
Title: Platform Director, Affinity Proteomics, SciLifeLab, Stockholm
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.